Tags

Type your tag names separated by a space and hit enter

Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
BMJ 2011; 344:d7901BMJ

Abstract

OBJECTIVE

To determine the effectiveness of an adjuvanted monovalent vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases.

DESIGN

Historical cohort study.

SETTING

Mandatory national reporting systems, 2 November 2009 to 31 January 2010, Denmark.

PARTICIPANTS

388,069 people under 65 years of age with a diagnosis in the past five years of at least one underlying disease expected to increase the risk of severe illness after influenza.

MAIN OUTCOME MEASURES

Laboratory confirmed H1N1 infection and influenza related hospital admission with laboratory confirmed H1N1 infection. Estimates of vaccine effectiveness were adjusted for age and underlying disease.

RESULTS

The effectiveness of pandemic vaccine against confirmed H1N1 infection 14 days after one dose of vaccine was 49% (95% confidence interval 10% to 71%). The effectiveness of vaccine against admission to hospital for confirmed H1N1 infection was 44% (-19% to 73%).

CONCLUSIONS

The adjuvanted monovalent vaccine against pandemic influenza A/H1N1 was offered late in the 2009-10 influenza season. Among chronically ill people, this vaccine offered protection against laboratory confirmed H1N1 infection but only offered non-significant protection against influenza related hospital admissions confirmed as H1N1 infection. This finding is of public health relevance because the population of chronically ill people is a major target group for pandemic vaccinations and because of the delayed availability of pandemic vaccines in a forthcoming pandemic.

Authors+Show Affiliations

Division of Epidemiology, Statens Serum Institut, Copenhagen, Denmark. hde@ssi.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22277542

Citation

Emborg, Hanne-Dorthe, et al. "Effectiveness of Vaccine Against Pandemic Influenza A/H1N1 Among People With Underlying Chronic Diseases: Cohort Study, Denmark, 2009-10." BMJ (Clinical Research Ed.), vol. 344, 2011, pp. d7901.
Emborg HD, Krause TG, Hviid A, et al. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ. 2011;344:d7901.
Emborg, H. D., Krause, T. G., Hviid, A., Simonsen, J., & Mølbak, K. (2011). Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ (Clinical Research Ed.), 344, pp. d7901. doi:10.1136/bmj.d7901.
Emborg HD, et al. Effectiveness of Vaccine Against Pandemic Influenza A/H1N1 Among People With Underlying Chronic Diseases: Cohort Study, Denmark, 2009-10. BMJ. 2011 Jan 25;344:d7901. PubMed PMID: 22277542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. AU - Emborg,Hanne-Dorthe, AU - Krause,Tyra Grove, AU - Hviid,Anders, AU - Simonsen,Jacob, AU - Mølbak,Kåre, Y1 - 2011/01/25/ PY - 2012/1/27/entrez PY - 2012/1/27/pubmed PY - 2012/3/7/medline SP - d7901 EP - d7901 JF - BMJ (Clinical research ed.) JO - BMJ VL - 344 N2 - OBJECTIVE: To determine the effectiveness of an adjuvanted monovalent vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases. DESIGN: Historical cohort study. SETTING: Mandatory national reporting systems, 2 November 2009 to 31 January 2010, Denmark. PARTICIPANTS: 388,069 people under 65 years of age with a diagnosis in the past five years of at least one underlying disease expected to increase the risk of severe illness after influenza. MAIN OUTCOME MEASURES: Laboratory confirmed H1N1 infection and influenza related hospital admission with laboratory confirmed H1N1 infection. Estimates of vaccine effectiveness were adjusted for age and underlying disease. RESULTS: The effectiveness of pandemic vaccine against confirmed H1N1 infection 14 days after one dose of vaccine was 49% (95% confidence interval 10% to 71%). The effectiveness of vaccine against admission to hospital for confirmed H1N1 infection was 44% (-19% to 73%). CONCLUSIONS: The adjuvanted monovalent vaccine against pandemic influenza A/H1N1 was offered late in the 2009-10 influenza season. Among chronically ill people, this vaccine offered protection against laboratory confirmed H1N1 infection but only offered non-significant protection against influenza related hospital admissions confirmed as H1N1 infection. This finding is of public health relevance because the population of chronically ill people is a major target group for pandemic vaccinations and because of the delayed availability of pandemic vaccines in a forthcoming pandemic. SN - 1756-1833 UR - https://www.unboundmedicine.com/medline/citation/22277542/Effectiveness_of_vaccine_against_pandemic_influenza_A/H1N1_among_people_with_underlying_chronic_diseases:_cohort_study_Denmark_2009_10_ L2 - http://www.bmj.com/cgi/pmidlookup?view=long&pmid=22277542 DB - PRIME DP - Unbound Medicine ER -